Study volume by peptide
Count of indexed research records returned for selected peptides.
Key takeaways
- Study count measures how much a peptide has been researched, not whether the research is positive or high quality.
- Semaglutide dwarfs the others largely because it is an approved drug with extensive clinical trials behind it.
- A low count often reflects research-only or preclinical status rather than a proven lack of effect.
Methodology & sources
Counts come from a standardized PubMed search run once per month, using each peptide’s primary name plus common synonyms, with duplicate records removed. We count indexed records of any type, including reviews, case reports, and preclinical work, so a single human trial and a single rat study each add one to the total. This is deliberately a volume measure, not a quality measure: it tells you how much attention a compound has received in the literature, not what that literature concluded. Where a peptide shares a name with an unrelated term, we constrain the query to reduce false matches, and we re-run the full set each month rather than incrementing, so corrections to PubMed indexing are reflected automatically.